Physician profile
Nisha I Kumar
NPI 1710226568
$1,030.59
in general payments reported to CMS, 2019-2025
13 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $462 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $303.97 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $154.74 | 2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $109.97 | 2024-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $96.23 | 2024-2025 | |
| Exact Sciences Corporation | $93.72 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Argenx US, INC. | $68.71 | 2024-2025 | Vyvgart Hytrulo |
| Hologic Sales and Service, LLC | $45.87 | 2024 | Aptima |
| Merck Sharp & Dohme LLC | $44.90 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $31.87 | 2024 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $30.00 | 2025 | |
| Pfizer INC. | $18.27 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.12 | 2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $14.22 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.